Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Public ClinicalTrials.gov record NCT00425555. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Study identification
- NCT ID
- NCT00425555
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 139 participants
Conditions and interventions
Conditions
Interventions
- Panobinostat Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2006
- Primary completion
- May 31, 2013
- Completion
- May 31, 2013
- Last update posted
- Aug 19, 2021
2007 – 2013
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham/ Kirklin Clinic Kirklin Clinic | Birmingham | Alabama | 35294-0006 | — |
| City of Hope National Medical Center | Duarte | California | 91010-3000 | — |
| University of California at Los Angeles Dept. of Hematology-Oncology | Los Angeles | California | 90095 | — |
| Florida Academic Dermatology Center | Miami | Florida | 33136 | — |
| Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) | Atlanta | Georgia | 30322 | — |
| Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia | Augusta | Georgia | 30912 | — |
| NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept. of NorthwesterUMed | Chicago | Illinois | 60611 | — |
| Indiana University Dept. of IU Cancer Center | Indianapolis | Indiana | 46202 | — |
| Boston Medical Center StudyCoordinator:CLBH589B2201 | Boston | Massachusetts | 02118 | — |
| Dana Farber Cancer Institute Deptof DanaFarberCancerInst(3) | Boston | Massachusetts | 02215 | — |
| University of Michigan Health System Michigan HouseClinTrialsOffice | Ann Arbor | Michigan | 48109 | — |
| Wake Forest University Baptist Medical Center OutpatientCmprehensivCancerCtr | Winston-Salem | North Carolina | 27157 | — |
| University Dermatology Consultants | Cincinnati | Ohio | 45219 | — |
| Oregon Health & Science University Dept. of OHSU Cancer Institute | Portland | Oregon | 97239 | — |
| University of Pittsburgh Medical Center Department of Dermatology | Pittsburgh | Pennsylvania | 15213 | — |
| MD Anderson Cancer Center/University of Texas StudyCoordinator:CLBH589B2201 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00425555, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2021 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00425555 live on ClinicalTrials.gov.